• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ICON plc Schedules First Quarter 2025 Earnings Conference Call

    3/31/25 6:30:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, April 30, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 1, 2025 at 8:00am ET.

    Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

    About ICON plc

    ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,900 employees in 106 locations in 55 countries as at December 31, 2024. For further information about ICON, visit: www.iconplc.com.

    This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

    ICON/ICLR-G

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250331784099/en/

    Kate Haven Vice President Investor Relations +1888 381 7923

    Get the next $ICLR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    4/29/2025$150.00Overweight → Neutral
    Analyst
    4/14/2025$157.00Buy → Hold
    TD Cowen
    4/10/2025$165.00Overweight → Equal Weight
    Barclays
    3/21/2025$250.00 → $200.00Buy → Neutral
    Goldman
    1/7/2025$263.00Outperform
    RBC Capital Mkts
    10/24/2024$340.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Neutral
    Redburn Atlantic
    9/18/2024$379.00Outperform
    Leerink Partners
    More analyst ratings

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICON plc downgraded by Analyst with a new price target

      Analyst downgraded ICON plc from Overweight to Neutral and set a new price target of $150.00

      4/29/25 8:06:12 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by TD Cowen with a new price target

      TD Cowen downgraded ICON plc from Buy to Hold and set a new price target of $157.00

      4/14/25 8:13:29 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • ICON plc downgraded by Barclays with a new price target

      Barclays downgraded ICON plc from Overweight to Equal Weight and set a new price target of $165.00

      4/10/25 8:49:19 AM ET
      $ICLR
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care